97.40
price down icon1.52%   -1.50
 
loading
前日終値:
$98.90
開ける:
$97.25
24時間の取引高:
5.66M
Relative Volume:
0.64
時価総額:
$123.23B
収益:
$28.73B
当期純損益:
$5.97B
株価収益率:
20.51
EPS:
4.75
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
-5.67%
1か月 パフォーマンス:
-5.62%
6か月 パフォーマンス:
+0.86%
1年 パフォーマンス:
+50.02%
1日の値動き範囲:
Value
$95.30
$97.58
1週間の範囲:
Value
$95.30
$105.17
52週間の値動き範囲:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1154)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
18,000
Name
Twitter
@GileadSciences
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

GILD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
97.39 123.23B 28.73B 5.97B 10.37B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
749.08 697.63B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
156.47 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.48 345.13B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
65.35 294.98B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.16 224.15B 53.22B 12.86B 14.85B 6.39

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
10:12 AM

Drugmaker Gilead pledges $11 billion investment in U.S. manufacturing - The Business Journals

10:12 AM
pulisher
09:20 AM

Gilead Sciences Increases Investment in U.S. Operations - Contract Pharma

09:20 AM
pulisher
09:03 AM

Earth Day Focus for Gilead SciencesEvery Action Has an Impact - ACCESS Newswire

09:03 AM
pulisher
08:41 AM

Gilead ups its US investment plans by $11 billion - Pharmaphorum

08:41 AM
pulisher
08:31 AM

Gilead Pumps $11B More Into US Manufacturing, Hopes To Add 3,000 Jobs - BioSpace

08:31 AM
pulisher
06:25 AM

Gilead tees up $11B in new US manufacturing, R&D investments - Fierce Pharma

06:25 AM
pulisher
05:58 AM

Gilead to invest $32 billion in US manufacturing and R&D - The Pharma Letter

05:58 AM
pulisher
May 07, 2025

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

Gilead announces $11 billion in new investments in US - MSN

May 07, 2025
pulisher
May 07, 2025

Gilead is latest to pledge allegiance to America with $32B manufacturing commitment - FirstWord Pharma

May 07, 2025
pulisher
May 07, 2025

Gilead boosts planned US investments by $11 billion amid tariff threat - MSN

May 07, 2025
pulisher
May 07, 2025

Gilead (GILD) to Boost U.S. Operations with $11 Billion Investment | GILD Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Gilead Sciences (GILD) Boosts U.S. Investment by $11 Billion - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Gilead Sciences Announces $11 Billion U.S. Investment BoostNews and Statistics - IndexBox

May 07, 2025
pulisher
May 07, 2025

Gilead to invest $32B in U.S.through 2030 (GILD:NASDAQ) - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing By Investing.com - Investing.com

May 07, 2025
pulisher
May 07, 2025

Gilead announces $11 billion in new investments in US By Reuters - Investing.com

May 07, 2025
pulisher
May 07, 2025

Gilead Sciences (GILD) U.S. Investment to Create $43B in Value to U.S. Economy - StreetInsider

May 07, 2025
pulisher
May 07, 2025

Gilead Boosts Planned US Investments by $11 Billion Amid Tariff Threat - US News Money

May 07, 2025
pulisher
May 07, 2025

Gilead To Invest $32 Bln In U.S. Manufacturing And R&D Through 2030 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025 - simplywall.st

May 07, 2025
pulisher
May 07, 2025

Fighting the World’s Most Devastating Diseases Is the Focus of This Installment of “The Centrifuge Sessions - CSRwire

May 07, 2025
pulisher
May 07, 2025

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - BioSpace

May 07, 2025
pulisher
May 07, 2025

Gilead (GILD): Livdelzi Shows Promising Results for PBC Treatment | GILD Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

GILD: Promising Results from Gilead's Bulevirtide Study for Chronic Hepatitis Delta | GILD Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Gilead to Invest $11 Billion to Bolster Domestic Operations - WSJ

May 07, 2025
pulisher
May 07, 2025

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire

May 07, 2025
pulisher
May 06, 2025

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

May 06, 2025
pulisher
May 06, 2025

Gilead (GILD) Sees Bearish Options Activity with Heavy Put Trading | GILD Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions" - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Gilead: Sure, Why Not, But Not The CDRs (GILD:CA) - Seeking Alpha

May 06, 2025
pulisher
May 05, 2025

What Are Wall Street Analysts' Target Price for Gilead Sciences Stock? - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo

May 05, 2025
pulisher
May 05, 2025

What Are Wall Street Analysts' Target Price For Gilead Sciences Stock? - Barchart.com

May 05, 2025
pulisher
May 03, 2025

Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience - GuruFocus

May 03, 2025
pulisher
May 03, 2025

Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN

May 03, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

Here's What to Expect From Gilead Sciences’ Next Earnings Report - MSN

May 02, 2025
pulisher
May 01, 2025

Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - The Business Journals

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences (GILD): A Promising Pick Amid Economic Uncertain - GuruFocus

May 01, 2025
pulisher
May 01, 2025

June 13th Options Now Available For Gilead Sciences (GILD) - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Gilead Agrees To Pay $202M To Settle Alleged Speaker Kickback Claims In FCA Suit - Law360

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - MSN

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue - MSN

May 01, 2025
pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in Gilead Sciences Inc. - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance

Apr 30, 2025
pulisher
Apr 29, 2025

Gilead Will Pay $202M In DOJ Deal Over Drug Kickbacks - Law360

Apr 29, 2025

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$52.08
price down icon 0.27%
drug_manufacturers_general PFE
$22.92
price up icon 0.46%
$268.02
price down icon 2.24%
drug_manufacturers_general MRK
$78.20
price down icon 1.10%
drug_manufacturers_general NVS
$110.16
price down icon 1.39%
大文字化:     |  ボリューム (24 時間):